Michael S. B. Edwards

Publication Details

  • Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen JOURNAL OF NEURO-ONCOLOGY Prados, M. D., Edwards, M. S., Rabbitt, J., Lamborn, K., Davis, R. L., Levin, V. A. 1997; 32 (3): 235-241

    Abstract:

    Between March 9, 1984 and January 29, 1992, 42 children with newly diagnosed symptomatic or previously diagnosed progressive low-grade gliomas received outpatient chemotherapy as their primary treatment. This study was a single arm, phase II trial designed to estimate the time to tumor progression and toxicity of this regimen. Procarbazine, 6-thioguanine, and dibromodulcitol were given before lomustine (CCNU) and vincristine was given 1 and 3 weeks after CCNU. Patients were treated for six treatment cycles or until the tumor progressed, whichever came first. Twenty-three patients had juvenile pilocytic astrocytomas, 11 had astrocytomas, one had oligodendroglioma, one had ganglioglioma, and six had radiographically diagnosed low-grade gliomas. The mean age of the patients was 5 years (median, 3 years). The median time to treatment failure was 132 weeks (95% confidence interval: 106, 186 weeks). Only eight patients have died the estimated 5-year survival rate is 78% (95% confidence interval, 60% 87%). There were two episodes of grade 4 neutropenia, and three episodes of grade 4 thrombocytopenia. This regimen was safe, able to be delivered in the outpatient setting, and produced prolonged periods of disease stabilization in children with low-grade gliomas.

    View details for Web of Science ID A1997WJ07900007

    View details for PubMedID 9049885

Stanford Medicine Resources:

Footer Links: